Companies /Healthcare

Tenaya Therapeutics Inc

NASDAQ: TNYA Biotechnology
$0.31
▼ $0.02 (−4.93%) today
Markets open · 9:40am ET

TNYA at a Glance

Valuation
Market cap
$73.6M
Profitability
Revenue (TTM)
$3.0M
EPS (TTM)
$-0.48
Price
52-week range
$0 – $1
Street target
$3.67

Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: TNYA tenayatherapeutics.com

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company that discovers and develops potentially curative therapies targeting the underlying genetic and biological drivers of heart disease. Its pipeline has three clinical-stage candidates:
- TN-201, an AAV-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), being studied in the MyPEAK-1 trial.
- TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), being studied in the RIDGE-1 Phase 1b/2 trial. It received FDA RMAT designation in September 2026.
- TN-301, a highly specific small-molecule HDAC6 inhibitor with potential in HFpEF, Duchenne muscular dystrophy and other cardiac, metabolic and muscular conditions. It is being readied for Phase 2 trials expected to begin in the second half of 2027.

The company uses integrated internal capabilities, including modality-agnostic target discovery and validation, to build a portfolio of genetics-based medicines for both rare genetic disorders and more prevalent heart conditions. Tenaya has begun recognizing collaboration revenue and funds operations primarily through equity capital. It reported cash of about $66.8 million as of September 30, 2026, and projects runway into the fourth quarter of 2027. Updated

TNYA Coverage

Frequently Asked Questions

What does Tenaya Therapeutics do?

Tenaya Therapeutics is a clinical-stage biotechnology company that discovers and develops potentially curative therapies targeting the underlying genetic and biological drivers of heart disease.

What is the TNYA stock price target?

The Wall Street consensus 12-month price target for TNYA is $3.67.